Drug Guide

Generic Name

Levodopa, Carbidopa, Entacapone

Brand Names Stalevo 50, Stalevo 75, Stalevo 100, Stalevo 125, Stalevo 150, Stalevo 200

Classification

Therapeutic: Parenteral antiparkinsonian agent

Pharmacological: Dopamine precursor, COMT inhibitor

FDA Approved Indications

  • Parkinson's disease

Mechanism of Action

Levodopa is converted to dopamine in the brain, alleviating Parkinsonian symptoms. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing central nervous system availability. Entacapone is a COMT inhibitor that prolongs the effect of levodopa by blocking its breakdown in the periphery.

Dosage and Administration

Adult: Dosage varies per formulation, typically titrated based on response. For Stalevo, dosing ranges from 50 mg to 200 mg of levodopa per tablet taken three or four times daily.

Pediatric: Not generally recommended for pediatric use.

Geriatric: Start at lower end of dosing range due to increased sensitivity to side effects.

Renal Impairment: Use caution; adjust dosing as needed.

Hepatic Impairment: No specific adjustments documented.

Pharmacokinetics

Absorption: Peak plasma levels of levodopa occur within 1 hour of oral administration.

Distribution: Widely distributed; crosses blood-brain barrier.

Metabolism: Levodopa is metabolized peripherally and centrally; entacapone inhibits COMT, reducing catecholamine breakdown.

Excretion: Metabolites are excreted primarily in urine.

Half Life: Levodopa: approximately 1-2 hours; entacapone: about 0.4 hours.

Contraindications

  • Hypersensitivity to any components.
  • Closed-angle glaucoma.
  • Non-selective MAO inhibitors taken within 2 weeks.

Precautions

  • Use with caution in cardiac, hepatic, or renal impairments. Monitor for neuropsychiatric effects, dyskinesias, and orthostatic hypotension. Pregnancy category C.

Adverse Reactions - Common

  • Nausea (Common)
  • Dyskinesias (Common)
  • Orthostatic hypotension (Common)

Adverse Reactions - Serious

  • Neuroleptic malignant syndrome (Rare)
  • Liver failure (Rare)
  • Daytime sleepiness or sudden sleep episodes (Uncommon)

Drug-Drug Interactions

  • Other dopamine agonists, MAO inhibitors, antipsychotics, certain antidepressants

Drug-Food Interactions

  • High-protein meals may reduce absorption.

Drug-Herb Interactions

N/A

Nursing Implications

Assessment: Monitor PD symptom control, blood pressure, and mental status.

Diagnoses:

  • Risk for falls related to hypotension or dizziness.
  • Impaired physical mobility.

Implementation: Administer with food to reduce nausea; avoid high-protein meals close to dosing; monitor for side effects.

Evaluation: Assess for improvement in motor symptoms and adverse reactions.

Patient/Family Teaching

  • Take medication exactly as prescribed.
  • Report new or worsening symptoms.
  • Avoid alcohol and certain foods that interfere with absorption.

Special Considerations

Black Box Warnings:

  • None specific, but caution advised related to neuropsychiatric events.

Genetic Factors: No specific genetic considerations.

Lab Test Interference: May cause false-positive urinary test results for certain drugs.

Overdose Management

Signs/Symptoms: Dopaminergic overdose may cause dyskinesias, hallucinations, or hypotension.

Treatment: Symptomatic and supportive care; no specific antagonist.

Storage and Handling

Storage: Store at room temperature, away from moisture and heat.

Stability: Stable for shelf life as indicated by manufacturer.

This guide is for educational purposes only and is not intended for clinical use.